Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK p.Gly1269Ala (p.G1269A) ALK p.Gly1269Ala (p.G1269A)
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho-ALK and phospho-AKT (detected by Western blot) at concentrations 10 fold lower than crizotinib. GI50 values were similar in Ba/F3 cells expressing either EML4-ALK wild-type or EML4-ALK G1269A (1.6nM and 2.2nM, respectively). In contrast, crizotinib treatment of Ba/F3 with EML4-ALK G1269A had survival GI50 of 130nM.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1342
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/552
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Ceritinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24675041
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ceritinib | Sensitivity | true |